Table DS1 Summary of data-sets and measures used for analysis

Data-set	Description	Time points used	Preference-based measure	Condition specific	Characteristics		
					n (baseline)	Age, years: mean(s.d.)	Female, %
Common mental health Assessing Health Economics of Antidepressants (AHEAD)[15]	RCT of the cost-effectiveness of antidepressants (three time points). Sample includes common mental health concerns – depression, mixed anxiety and depressive disorders, and phobias	Baseline 6 months 12 months	EQ-5D	HADS	327	43.1 (15.4)	67.0
Psychological interventions for postnatal depression (PoNDER)[16]	Study of two psychologically informed interventions for women with postnatal depression	Baseline 6 months 12 months	SF-6D	CORE-OM	2,640	31.5 (5.1)	100
Improving Access to Psychological Therapies cohort study (SDO-IAPT)[17]	Evaluation of the outcomes from two IAPT demonstration sites. Sample reports common mental health condition	Baseline 4 months 8 months	SF-6D	CORE-OM	527	40.9 (14.2)	72.3
Common mental health and personality disorders POPMACT[18,19]	RCT of manual-assisted cognitive therapy (MACT) versus treatment as usual in recurrent self-harm. Sample includes patient with diagnoses of common mental health conditions and personality disorders leading to self-harm	Baseline	EQ-5D	HADS	480	32.0 (11.2)	
Personality disorders Study of cost effectiveness of personality disorder treatment (SCEPTRE)[20]	Dutch study of adult patients with personality disorders (UK EQ-5D tariff used for comparability).	Baseline 12 months	EQ-5D	DSM-IV personality disorder category	932	35.1 (9.8)	68.1
Schizophrenia/personality disorders Quality of Life following Adherence Therapy (QUATRO)[21]	Multicounty RCT of adherence therapy in patients with a clinical diagnosis of schizophrenia for needed continuing antipsychotic medication for at least a year from assessment, and had evidence of clinical instability in the year before assessment		EQ-5D SF-6D	BPRS-E	409	41.5 (11.5)	59.9
Multicenter study of Art Therapy In Schizophrenia: Systematic Evaluation (MATISSE)[22]	RCT of group art therapy for people with a clinical diagnosis of schizophrenia.	Baseline 12 months	EQ-5D	PANSS	417	41.0 (11.5)	33.3

RCT, randomised controlled trial; HADS, Hospital Anxiety and Depression Scale; CORE-OM, Clinical Outcomes in Routine Evaluation – Outcome Measure; BPRS-E, Brief Psychiatric Rating Scale Expanded; PANSS, Positive and Negative Syndrome Scale.

Table DS2 Descriptive statistics and completion rates

	Number completing measure	Mean	s.d.	Completion, %
Common mental disorders – EQ-5D				
AHEAD				
EQ-5D				
Baseline	320	0.604	0.264	97.86
6 months	174	0.752	0.257	
12 months	164	0.777	0.249	
HADS-A				
Baseline	324	13.11	3.48	99.08
6 months	202	8.78	3.54	
12 months	169	8.30	3.59	
HADS-D				
Baseline	324	10.50	3.87	99.08
6 months	202	4.94	3.92	
12 months	169	4.34	3.99	98.83
Common mental disorders – SF-6D				
SDO-IAPT				
SF-6D				
Baseline	504	0.613	0.13	95.6
4 months	425	0.645	0.14	
8 months	390	0.668	0.15	
CORE-OM clinical score				
Baseline	494	20.06	7.81	93.74
4 months	409	16.58	8.53	
8 months	403	15.09	8.83	
PoNDER				
SF-6D				
Baseline	2600	0.669	0.09	97.82
6 months	2614	0.822	0.14	
12 months	1697	0.839	0.13	
CORE-OM clinical				
Baseline	2640	5.23	4.97	99.32
6 months	2641	4.73	4.91	
12 months	1713	4.52	4.85	
Common mental and personality disorders				
POPMACT				
EQ-5D baseline	476	0.503	0.320	99.20
HADS-A baseline	479	14.13	3.94	99.80
HADS-D baseline	478	11.22	4.58	99.58
Schizophrenia				
MATISSE				
EQ-5D				
Baseline	409	0.676	0.271	98.08
12 months	357	0.678	0.297	
PANSS total score				98.56
Baseline	411	79.45	24.19	

	N	Mean	SD	%
12 months	334	76.15	27.11	
QUATRO				
EQ-5D				96.33
Baseline	394	0.679	0.291	
12 months	367	0.710	0.286	
SF-6D				
Baseline	383	0.668	0.125	93.64
12 months	367	0.682	0.134	
BPRS-E total				
Baseline	406	45.17	13.02	99.27
12 months	371	37.71	10.54	
Personality disorders				
SCEPTRE - EQ-5D				
Baseline	899	0.566	0.284	99.34
12 months	693	0.741	0.249	

AHEAD, Assessing Health Economics of Antidepressants; EQ-5D, EuroQoL-5D; HADS-A, Hospital Anxiety and Depression Scale, anxiety subscale; HADS-D, Hospital Anxiety and Depression Scale, depression subscale; SDO-IAPT, Improving Access to Psychological Therapies cohort study; SF-6D, Short Form-6D; CORE-OM, Clinical Outcomes in Routine Evaluation – Outcome Measure; PoNDER, psychological interventions for postnatal depression; POPMACT, Prevention of Parasuicide with Manual Assisted Cognitive behaviour Therapy; MATISSE, Multicenter study of Art Therapy in Schizophrenia: Systematic Evaluation; PANSS, Positive and Negative Syndrome Scale; QUATRO, Quality of Life following Adherence Therapy for People Disabled by Schizophrenia and their Carers; BPRS-E, Brief Psychiatric Rating Scale Expanded; SCEPTRE, Study on Cost-Effectiveness of Personality Disorder Treatment.

Table DS2 Known group validity of EQ-5D and SF-6D

	Groups	EQ-5D N	EQ-5D Mean (s.d.)	EQ-5D ES	SF-6D N	SF-6D Mean (s.d.)	SF-6D ES
Common mental disorders							
AHEAD							
HADS-A caseness	No case	98	0.671 (0.25)		-	-	-
	Probable case	219	0.573 (0.27)	0.37	-	-	-
				P=0.002	-	-	-
HADS-D caseness	No case	163	0.677 (0.24)		-	-	-
	Probable case	154	0.525 (0.27)	0.60	-	-	-
				P<0.001	-	-	-
SDO-IAPT							
CORE-OM clinical	Non clinical	-	-	-	53	0.740 (0.11)	
	Clinical	-	-	-	422	0.597 (0.12)	*1.24*
		-	-	-			*P*<0.001
PoNDER							
CORE-OM clinical	Non clinical	-	-	-	2241	0.683 (0.08)	
	Clinical	-	-	-	399	0.595 (0.07)	*1.16*
		-	-	-			*P*<0.001
Common mental and personality disorders							
POPMACT							
HADS-A caseness	No case	84	0.718 (0.28)		-	-	-
	Probable case	392	0.457 (0.31)	0.88	-	-	-
				P<0.001	-	-	-
HADS-D caseness	No case	210	0.622 (0.30)		-	-	-
	Probable case	265	0.410 (0.30)	*0.71*	-	-	-
				P<0.001	-	-	-
Personality disorders							
Number of diagnoses	No Personality Disorder	84	0.648 (0.24)		-	-	-
	1 Personality Disorder	248	0.606(0.27)	0.18	-	-	-
	2 Personality Disorder	95	0.549 (0.30)	0.21	-	-	-
	3 Personality Disorder	42	0.493 (0.29)	0.18	-	-	-
	≥4 Personality Disorders	41	0.416 (0.27)	0.27	-	-	-
				P=0.202	-	-	-
Diagnosis [a]	None	113	0.657 (0.23)		-	-	-
	Borderline	41	0.581 (0.29)	0.32[b]	-	-	-
	Avoidant	69	0.638 (0.25)	0.08[b]	-	-	-
	Obsessive-compulsive	55	0.578 (0.27)	0.34[b]	-	-	-
	Depressive	60	0.525 (0.28)	0.56[b]	-	-	-
	Not otherwise specified	142	0.616 (0.29)	0.17[b]	-	-	-
				P=0.042	-	-	-
Schizophrenia							
QUATRO							
	None/mild (24–31)	56	0.831 (0.16)		56	0.727 (0.09)	
BPRS-E	Moderate (32–41)	112	0.744 (0.23)	0.54*	112	0.682 (0.12)	0.47
	Marked (42–53)	119	0.652 (0.28)	0.40*	119	0.664 (0.12)	0.16

		N			N		
	Severe (>53)	88	0.543 (0.36)	0.39 *P*<0.001	88	0.625 (0.13)	0.31 *P*<0.001
MATISSE PANSS	Normal/mild (30–58)	86	0.747 (0.24)		-	-	-
	Moderate (59 –75)	114	0.693 (0.23)	0.23	-	-	-
	Marked (76 –95)	112	0.660 (0.27)	0.14	-	-	-
	Severe (>95)	92	0.606 (0.33)	0.20 *P*=0.003	-	-	-

*P<0.05 in test of difference between adjacent severity groups.

a. Sample of those with a single diagnosis.

b. Compared with the group with no personality disorder.

EQ-5D, EuroQoL-5D; SF-6D, Short Form-6D; AHEAD, Assessing Health Economics of Antidepressants; POPMACT, Prevention of Parasuicide with Manual Assisted Cognitive behaviour Therapy; QUATRO, Quality of Life following Adherence Therapy for People Disabled by Schizophrenia and their Carers; MATISSE, Multicenter study of Art Therapy in Schizophrenia: Systematic Evaluation; SDO-IAPT, Improving Access to Psychological Therapies cohort study; PoNDER, psychological interventions for postnatal depression; HADS-A, Hospital Anxiety and Depression Scale, anxiety subscale; HADS-D, Hospital Anxiety and Depression Scale, depression subscale; CORE-OM, Clinical Outcomes in Routine Evaluation – Outcome Measure; BPRS-E, Brief Psychiatric Rating Scale Expanded; PANSS, Positive and Negative Syndrome Scale.

Fig. DS1 Scatterplots/locally weighted scatterplot smoothing (LOWESS) lines for the common mental health and mixed diagnosis conditions.

EQ-5D, EuroQoL-5D; SF-6D, Short Form-6D; AHEAD, Assessing Health Economics of Antidepressants; POPMACT, Prevention of Parasuicide with Manual Assisted Cognitive behaviour Therapy; SDO-IAPT, Improving Access to Psychological Therapies cohort study; PoNDER, psychological interventions for postnatal depression; HADS-T, Hospital Anxiety and Depression Scale, overall score; CORE-OM, Clinical Outcomes in Routine Evaluation – Outcome Measure.

Fig. DS2 Scatterplots/locally weighted scatterplot smoothing (LOWESS) lines for the schizophrenia and personality disorder samples.

EQ-5D, EuroQoL-5D; SF-6D, Short Form-6D; QUATRO, Quality of Life following Adherence Therapy for People Disabled by Schizophrenia and their Carers; MATISSE, Multicenter study of Art Therapy in Schizophrenia: Systematic Evaluation; BPRS, Brief Psychiatric Rating Scale; PANSS, Positive and Negative Syndrome Scale.

QUATRO (EQ-5D)

QUATRO (SF-6D)

MATISSE